Concurrent Investment Advisors LLC Acquires 2,166 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Concurrent Investment Advisors LLC grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 39.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,680 shares of the medical research company's stock after buying an additional 2,166 shares during the period. Concurrent Investment Advisors LLC's holdings in IQVIA were worth $1,354,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC increased its stake in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock valued at $703,000 after purchasing an additional 2,537 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in IQVIA by 57.0% in the fourth quarter. Jones Financial Companies Lllp now owns 1,215 shares of the medical research company's stock worth $239,000 after acquiring an additional 441 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in IQVIA in the fourth quarter worth approximately $60,000. Proficio Capital Partners LLC bought a new position in IQVIA in the fourth quarter worth approximately $29,091,000. Finally, Callan Family Office LLC bought a new position in IQVIA in the fourth quarter worth approximately $355,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

Shares of IQV stock traded down $2.80 during trading on Friday, hitting $162.73. The company had a trading volume of 1,156,699 shares, compared to its average volume of 1,659,159. The stock's 50-day moving average is $151.77 and its two-hundred day moving average is $172.43. The stock has a market capitalization of $28.15 billion, a price-to-earnings ratio of 22.17, a price-to-earnings-growth ratio of 1.84 and a beta of 1.30. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 2.19.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The firm had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. During the same quarter in the previous year, the company posted $2.54 earnings per share. The company's revenue was up 2.5% compared to the same quarter last year. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on IQV shares. UBS Group decreased their price target on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Evercore ISI boosted their price target on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and dropped their price target for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Truist Financial dropped their price target on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Finally, Hsbc Global Res cut shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, IQVIA currently has an average rating of "Moderate Buy" and a consensus price target of $222.45.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.